Table 1 Summary of all treatments performed on mice with SU-DHL-6–derived tumors.

n mice (died ≤1 week) refer to the total numbers of mice treated and, in parentheses, those that died within the first week. The causes for these early deaths remain unclear and may be due to the overall experimental burden imposed on the animals; surviving animals showed no signs of distress. Regression: Percentages of animals scored as showing tumor regression at the indicated time points, with the scored/total numbers in parentheses. At day 19, partial and complete regressions were defined as residual tumor volumes ≤50% and ≤10% of the initial volume, respectively. Animals showing complete regression at day 19 were followed until day 120 and sacrificed when tumors reached a diameter of 2 cm. Animals reaching the end point of 120 days had no detectable residual tumor. Compacted liver: “Yes” indicates that the postmortem examination revealed a compacted liver lobule morphology.

Tigecycline,
mg/kg
Venetoclax,
mg/kg
n mice
(died ≤1 week)
Regression: % tumor-free (n)Compacted
liver
Day 19: PartialDay 19: CompleteDay 120
0.9% NaCl14
Vehicle13
757Yes
10012Yes
2514
506
1007
1001007 (3)75% (3/4)75% (3/4)Yes
100506100% (6/6)100% (6/6)Yes
1005010 (2)12.5% (1/8)87.5% (7/8)50% (4/8)Yes
10025757% (4/7)Yes
7510010 (5)20% (1/5)80% (4/5)60% (3/5)Yes
751008 (3)100% (5/5)60% (3/5)Yes
7550812.5% (1/8)87.5% (7/8)75% (6/8)Yes
50507100% (7/8)42% (3/7)
25100728% (2/7)